Stefan Chen, PhD - Engagement Manager, McKinsey & Company
Stefan Chen is an engagement manager in McKinsey & Company's Shanghai office. He joined McKinsey New York office over 2 years ago and transferred to Shanghai office after a year. His consulting experience has been focused on Healthcare industry across broad spectrum of topics. At McKinsey, Stefen led a growth strategy study for a Gx drug player in China, a war game workshop for a leading pharmaceutical company to explore competitive strategies, a study to understand R&D capability landscape in China for a leading NGO; helped a leading pharmaceutical company to assess growth strategy in 5 years and design implementation plan for key functions; assessed growth opportunities for a large pharmaceutical company and helped build risk management model; worked on sourcing strategy for a large pharmaceutical company and helped implementation in a BU; developed in-licensing network with major academic centers for a pharmaceutical client. He holds a PhD in Immunology of Harvard University.
Ying Chen, PhD - Senior Engagement Manager, McKinsey & Company
Ying Edna Chen is an Engagement Manager in McKinsey & Company’s Beijing office. Her selective past engagements include: detailed business action plans of a healthcare nutritional unit for a leading MNC food and healthcare product company; market potential assessment and growth strategy for a leading life sciences company; transformation strategy and distribution model for a leading vaccines company; TCM market assessment, and screening of leading products and players for value creation opportunities for a global pharma company; help building a winning legal structure to enable sales growth in China for a mid-sized MNC pharmaco; business entry strategy for pharma contract manufacturing and generics manufacturing for a private investor; business development study in Traditional Chinese Medicine for a large pharmaco’s OTC business; global product launch case study for a leading pharmaco in Diabetes; international brand strategy for a foreign health payor; organization restructure for a major multinational pharmaco in China; growth strategy for a Japanese pharmaco in the oncology TA; 5-year growth strategy for a major multinational medical device company in China.
Before joining McKinsey, Dr. Chen also had extensive research experience in bioinformatics and biotechnology in the University of Chicago at Chicago, IL. Ms. Chen received her BS degree (majored in Biochemistry and Molecular Biology) from Peking University in Beijing, China, and her PhD degree in Biology from the University of Rochester at Rochester, New York, USA.
Franck Le Deu, MBA - Principal, McKinsey & Company
Franck Le Deu is a Partner in McKinsey & Company’s Shanghai office and Co-leader of McKinsey’s Greater China Healthcare practice. He has over 8 years of experience serving pharmaceutical multinationals in the US, Europe, and emerging markets. He received his MBA from Kellogg and started in the New Jersey office before joining our Greater China office in 2005. His recent engagements include: China growth strategy and sales/distribution model for a leading Medical Devices manufacturer; growth strategy for a leading vaccines manufacturer in China; 5-year growth strategy for the China operations of a mid-size pharma multinational; assessing China’s potential for early stage research and development activities for a leading pharma multinational; 5-year growth road-map for a leading pharma MNC in Russia; understanding the impact of the on-going healthcare reform in the UAE on the pharma market opportunities; mid term growth initiative opportunities for a leading pharma MNC in Indonesia; branded generics strategy in South East Asia for a leading MNC; merger integration across Asia Pacific for a leading pharma MNC.
Frank Grams, PhD - Executive Director, Roche Global Pharma Partnering
Frank has been instrumental in setting up the Shanghai office of Roche Pharma Partnering. The office is strengthening Roche’s presence in the region and is mainly responsible for partnering activities in Korea, Singapore and Greater China including Taiwan and Hong Kong. Prior to taking up this post, from 2006 Frank was Global Head, Drug Delivery Partnering, responsible for both the strategic and life-cycle management activities related to drug delivery partnering. Frank was a Global Alliance Director from 2002, managing pivotal research alliances such as Chugai, Evotec, SGX, Syrrx and Biotie. He has been involved in about 100 transactions including product and technology deals, in- and out-licensing opportunities and also an acquisition. Frank joined the Roche Pharma Partnering team as Head of Opportunity Surveillance in July 2001, having previously worked in various research functions in Roche and at Boehringer Mannheim GmbH. Frank has a degree in chemistry from the University of Heidelberg and a PhD from the Technical University of Munich within the group of Nobel laureate Robert Huber (Max-Planck-Institute for Biochemistry at Martinsried). His more than 40 papers have been published in well known peer-reviewed journals such as Nature Structural Biology, Journal of Molecular Biology etc. and have been cited about a thousand times. Five of them have been cited even more than a hundred times. He is also the co-author on 19 patents and patent applications.
Lu Huang, MD, MBA - Director, Morningside
Since joined Morningside 5 years ago, Dr. Huang has led over a dozen healthcare/life-science investments in China and the US. Prior to joining Morningside, Dr. Huang served as a Marketing Associate in the Public Relations & Marketing group at Continuum Health Partners, a five-hospital partnership in New York City. Dr. Huang holds her medical degree from Shanghai Second Medical University, trained and practiced in Obstetrics/Gynecology, and her MBA degree from St. John’s University, New York.
Kewen Jin, PhD - General Manager, Charles River Greater China
Kewen Jin is currently General Manager of Charles River Laboratories (CRL) China preclinical service company. He was founder/CEO of BioExplorer, a preclinical CRO which formed a JV with CRL in 2007. Kewen has co-founded and served as key executive (CEO, CBO, and founding partner) for three other companies in the R&D outsourcing, drug discovery, and consulting. He served as advisor to several MNC pharma and healthcare companies, major consulting and investment firms. Previously, he was a marketing and international operation executive with Wyeth, first five years in the U.S. , then two years in Beijing. He is a Senior Advisor to Shanghai Pudong Government. He was granted the 2005 Magnolia Award, which the Shanghai government grants to individuals making major contribution to the development of Shanghai. He is a member of the Board of Directors for Bayhelix and Sino American Pharmaceutical Association (SAPA), two leading Chinese life science professional organizations. He was trained in medicine (Shanghai Jiaotong University School of Medicine), biology (Rockefeller), finance (Columbia).
Lan Kang, MBA - Client Partner, Korn/Ferry (Shanghai) Human Capital Consulting Co., Ltd.
Ms. Lan Kang is a Client Partner at Korn/Ferry International’s Greater China Office. She is specializing in senior executive search in Healthcare/ Life Science market in China. Prior to joining the Firm, Ms. Kang spent over 4 years working on management consulting at McKinsey & Company’s Greater China office and was a core member of its Healthcare Practice. She assisted leading pharmaceutical, medical devices and other Healthcare related multinational and local companies in strategy development, operation improvement, and change management projects. Prior to that, Ms. Kang specialized in Cancer Research in the U.S. for five years, first as a researcher in the Surgery Department at Memorial Sloan Kettering Cancer Center in NYC, then as a Research Scientist working on drug discovery at Wyeth, Pearl River, NY. Ms. Kang is not only well-connected in the Life Science field in China, but also in close contact with the Chinese Pharmaceutical / Biotech professional communities in the US. She is also a member of BayHelix group, a non-profit organization of leaders of Chinese origin in the global life sciences and healthcare community. Born in Nanjing, Ms. Kang obtained her Bachelor’s degree in Biological Science and Technology from Zhejiang University in China, and a Master’s degree in Biochemistry from Tulane University in the U.S. She also received an MBA in the Healthcare Program with Honors from The Wharton School, University of Pennsylvania, U.S.A.
Bin Li, PhD - Senior Research Analyst/Executive Director, Greater China Healthcare, Morgan Stanley
Dr. Bin Li is a senior research analyst at Morgan Stanley (Hong Kong) and leads the research coverage on China healthcare industry. He is ranked No.1 analyst in Asia healthcare sector by Institutional Investors (II) survey. Previously, he was a senior healthcare research analyst at Merrill Lynch (Hong Kong) and responsible for the firm’s stock research efforts on Asia healthcare. Before moving to Hong Kong, he was a key member of a top pharmaceutical research team (based in Merrill Lynch New York) ranked by Wall Street investment professionals in several well-recognized polls. Bin Li has close to 20 years experience in healthcare, including ten years as a sell-side healthcare analyst covering global healthcare companies. He received his PhD in biochemistry and MBA from New York University and bachelor degree from Fudan University, China. Prior to his position at Merrill Lynch, he worked at Merck Research Laboratory as a scientist and Goldman Sachs as a stock analyst. His investment research covers topics such as company financial status, R&D pipeline updates, product market assessments, physician surveys, prescription trends, price analysis, patent and legal challenges, regulatory policies, and legislative/political environment. He forecasts company earnings and constructs market size models based on interactions with senior executives, industry consultants, opinion leaders in medical communities, and other primary sources.
Joseph S. McCracken, DVM - Head of Pharma Partnering Asia, Roche Global Pharma Partnering
Joseph McCracken is currently the Asia Regional Head for Roche Pharma Partnering, and General Manager, Roche Pharma Japan. In this role Dr. McCracken is responsible for Roche’s pharmaceutical partnering activities throughout Asia, and he is currently based in Tokyo, Japan. Prior to joining the Roche Pharma Partnering organization, Dr. McCracken held the position of Vice President, Business Development at Genentech for more than 10 years. At Genentech Joe was responsible for all business development activities at the Company, including the identification and negotiation of collaboration and licensing agreements with academic institutions, biotechnology companies and pharmaceutical companies throughout the world. Dr. McCracken returned to Genentech in 2000 after a seven-year absence, during which he held positions as President of Technology Licensing and Alliances at Aventis, and Vice President of Worldwide Business and Technology Development at Rhone-Poulenc Rorer S.A. During his earlier time with Genentech, Dr. McCracken served in many capacities, culminating in positions as Director of Business Development and Representative Director of Genentech Ltd., Genentech’s wholly owned subsidiary in Japan. McCracken has more than 25 years of experience in technical, business development and market development roles with biotechnology and pharmaceutical companies. He holds a Bachelor of Science in Microbiology, a Master of Science in Pharmacology and a Doctorate of Veterinary Medicine from The Ohio State University.
Greg B. Scott - President and Founder, ChinaBio® LLC
Mr. Scott has helped launch over thirty life science startups in the U.S. and China as a founder, investor and advisor. He founded the ChinaBio® LLC in January 2007 to help fund and mentor early stage life science companies in China, and provide consulting and research services to pharma and biotech companies with business interests in China. Mr. Scott is also the president and co-founder of Life Science Angels, an angel investment group that has funded 30 biotechnology and medical device companies since 2005, and executive editor of ChinaBio® Today. He is also a strategic adviser to ChinaSF, an initiative of the Mayor of San Francisco to connect China and San Francisco business interests. He previously held senior executive positions at Price Waterhouse, Capgemini and MCI, and was co-founder of a 200-person consulting firm. Mr. Scott attended University of Missouri, where he studied mathematics, microbiology and computer science.
Lefei Sun, PhD - Associate, OrbiMed Asia
Lefei Sun is an Associate on the OrbiMed Asia team. Prior to joining OrbiMed, Mr. Sun worked at Orchid Asia Investment Group focusing on private equity investments in healthcare, consumer goods and services industries. In Orchid Asia, he was also actively involved in portfolio management as the board observer of an interventional medical device company. Previously, he worked for McKinsey Company specializing in healthcare practice in China. Mr. Sun holds a BS degree in physics and mathematics from Tsinghua University in China and was a PhD student in neurosciences in the Johns Hopkins University School of Medicine.
Jonathan Wang, PhD, MBA - Senior Managing Director, OrbiMed Asia
Dr. Jonathan Wang is a Senior Managing Director, at OrbiMed Asia. He is a general partner at OrbiMed’s Asia-focused VC fund. Previously, he was General Manager at Burrill Greater China Group and worked for WI Harper Group and Walden International, two pioneers in the Asia-related VC industry. At WI Harper, Dr. Wang was a Managing Director, overseeing the firm’s life sciences activities worldwide. There he co-founded and incubated Bridge Laboratories. Dr. Wang is a Board Director at ForteBio, Inc. He is also co-founder and former Chairman of The BayHelix Group, an organization of Chinese life sciences business leaders. He holds a PhD in Molecular Neurobiology from Columbia University, where he obtained scientific training under the supervision of Dr. Eric Kandel, a Nobel Laureate. Dr. Wang also earned an MBA from Stanford University.
Zoe Wang, PhD, JD - Partner, Perkins Coie LLP
Zoe Wang focuses her practice on patent infringement and validity opinions, patent prosecution, freedom-to-operate analyses, patentability analyses, technology transfers and licensing. Her work involves technologies in the fields of life sciences, nanotechnologies, data processing, and devices. She also has experience advising clients in public offerings and private placements of equity and debt securities, mergers and acquisitions, counseling companies on general corporate matters, and advising clients with respect to the Securities Act of 1933, the Securities Exchange Act of 1934 and the Sarbanes-Oxley Act of 2002. She received her JD from Columbia University School of Law in 1999 and her PhD in cell biology and biophysics from Duke University in 1996.
Michael J. Wise, JD - Partner, Perkins Coie
Michael Wise is a partner in the firm's Intellectual Property Group. He has extensive experience in litigating patents, trademarks, and trade secrets in federal and state court. Michael has also handled numerous patent interferences before the Board of Patent Appeals and Interferences. He has litigated a wide variety of technologies including antibodies, immunoassays, recombinant genes and proteins, medical devices, software, electronics, and laser bar code scanners. Michael has the ability to take complicated technologies and explain them to either a sophisticated panel of interferences judges or explain them to lay person. Michael has spent many years counseling start-up companies with respect to their intellectual property needs and concerns. Last year, he was recognized by the Daily Journal as one of the top 25 patent portfolio managers in California. Michael Wise also leads the firm's expansion into the China market with the Shanghai and Beijing offices. He represents both US and Chinese clients in patent litigation, patent due diligence and patent portfolio management. Earlier this year, he defended a Chinese client in a Section 337 action before the International Trade Commission. Michael received his BS in Biology from University of California, Los Angeles, and his JD from Loyola Law School, Los Angeles.